Podcasts about rcc

Message from Terry Williams on December 21, 2025

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk, Dr. Riccardo Bertolo and Assoc. Prof. Carlotta Palumbo share and discuss highlights of the important kidney cancer developments for 2025. They summarise the developments in diagnostics and early detection, systemic therapy and perioperative treatment. They also talk about surgical and robotics innovations, tumour biology, and anticipated advances expected in 2026.To learn more on the highlights discussed in this podcast, check out this report on kidney cancer highlights in 2025.  For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Brian, Tom and Silke discuss the highlights of RCC for 2025

14-12-2025- When God Moves- Ps114- Stand alone- Mark Koekemoer by RCC

Message from Terry Williams on December 14, 2025

Dr. Norina Columbaro brings nearly three decades of instructional design wisdom to this thought-provoking conversation about performance-focused learning. Drawing from her extensive experience across 60+ organizations worldwide, she reveals how the most successful learning initiatives prioritize measurable performance outcomes rather than just creating training materials.Whether you're new to instructional design or a seasoned professional, you'll appreciate Dr. Columbaro's practical insights about influencing stakeholders, working with subject matter experts, and maintaining focus on performance outcomes in your learning initiatives. Her passion for connecting people with knowledge shines through in every aspect of this enlightening conversation.

07-12-2025- Give Thanks Always- 1 Thes 5:16-18- Stand Alone- Matt Johnson by RCC

Message from Terry Williams on December 7, 2025

Video Block Double-click here to add a video by URL or embed code. Learn more PRESENTATION LIFE GROUP NOTES DEVOTIONAL Daily Prayer Permalink

30-11-2025- The Gospel of Luke- Luke 15 : 1-10- Devin Stickells by RCC

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included: • The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment • The impact of disease progression on treatment decisions • Side effect management and the importance of palliative care • The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

Message from Terry Williams on November 30, 2025

Video Block Double-click here to add a video by URL or embed code. Learn more PRESENTATION LIFE GROUP NOTES Permalink

Former White House stenographer Mike McCormick joins Dr. Jerome Corsi for one of the most explosive interviews ever aired on Corsi Nation. Drawing from his new book, An Almost Insurmountable Evil: How Obama's Deep State Defiled the Catholic Church and Executed the Wuhan Plandemic, McCormick reveals how the Obama–Biden political machine allegedly infiltrated and manipulated the Catholic Church, empowered corrupt clergy, and used religious authority to influence global politics.McCormick details:

23-11-2025- The Gospel of Luke- Luke 14:25-35- Bryce Biggs by RCC

Message from Rodney Bartlett on November 23, 2025

Video Block Double-click here to add a video by URL or embed code. Learn more PRESENTATION LIFE GROUP NOTES Devotional Permalink

UROONCO RCC chief editor Dr. Carmen Mir (US) talks to Dr. Lorenzo Bianchi (IT) on his lecture "RCC with venous thrombosis: optimal imaging for surgical planning and imaging-guided surgery".This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Comments? Questions? Send us a message!Steve Marquez is husband to Monica, and father of Cody, Jared, and Andrew. Steve is a pastor, a teacher, a former church planter, a musician, a former journalist, photographer, and founder of a non-profit ministry called Stage 4 Ministries. Monica, Steve's wife, is her husband's co-laborer in life and also in ministry, She is a super effective and fruitful minister in her own right.  In 2014, the Marquez family received astonishing and shocking news. Steve was diagnosed with stage 3 Renal Cell Carcinoma (RCC), which is kidney cancer. Later, it was discovered that he had stage 4, metastatic RCC. Eventually, he and Monica started Stage 4 Ministries. That story is told in podcast 158 of Strength for Today's Pastor.So, what's new with Stage 4 Ministries? Steve and Monica are excited about Solace, a new way of serving not only potential end of life cancer patients, but also the ones who provide care (caregivers). Solace is a ministry tool and template for any church seeking to provide such care, not only to church congregants, but also to the surrounding community.Listen in for more, and find out how you can gain a deep dive understanding of how the Lord might use Solace and Stage 4 Ministries in your ministries.Spoiler alert: the exciting, God-glorifying story of Steve's healing is also contained in this episode!ResourcesBook: Grace for the BattleBlog: https://stmarq.substack.com/Website: https://www.stage4ministries.com/For Poimen Ministries, its staff, ministries, and focus, go to poimenministries.com. To contact Poimen Ministries, email us at strongerpastors@gmail.com. May the Lord revive His work in the midst of these years!

Message from Aaron Lewis on November 16, 2025

In today's episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with genitourinary (GU) cancer expert Scott T. Tagawa, MD, MS, FACP, FASCO, about the rapidly evolving treatment paradigms for prostate and kidney cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Tagawa is a professor of medicine and urology at Weill Cornell Medicine, as well as an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center in New York, New York. Their conversation began with a focus on prostate-specific membrane antigen (PSMA)–positive prostate cancer. Dr Tagawa explained that PSMA is a cell surface protein, and that PSMA imaging agents are commonly used to assess biochemical recurrence and perform initial disease staging. He noted that therapy-related adverse effects are often site-specific, including dry mouth/change in taste, and myelosuppression from the radiation payload. For monitoring long-term safety, Dr Tagawa emphasized that renal function must be tracked. Beyond PSMA, other prostate cancer targets include TROP-2, B7-H3, and markers specific to aggressive or neuroendocrine variants, such as DLL3, he reported. In advanced GU cancers, circulating tumor DNA (ctDNA) testing is increasingly important, Dr Tagawa highlighted. In prostate cancer, ctDNA testing is used to assess homologous recombination deficiency (HRD) status and BRCA expression, he said, explaining that evidence for the use of ctDNA testing in GU cancers stems from findings with this type of assay to evaluate minimal residual disease levels in urothelial cancer. He noted that studies show that if patients with urothelial cancer become ctDNA positive within the first year of receiving neoadjuvant chemotherapy, they benefit from treatment with atezolizumab (Tecentriq). Similarly, he stated that patients with previously untreated HRD-positive metastatic prostate cancer also see a progression-free survival benefit when a PARP inhibitor is added to an androgen deprivation therapy/androgen receptor pathway inhibitor backbone. Shifting the conversation to the management of frontline advanced clear cell renal cell carcinoma (RCC), the experts reviewed standard approaches, which involve an immune-oncology (IO) agent plus either a CTLA-4 inhibitor or a VEGF TKI. Tagawa noted that IO/VEGF TKI combinations may be preferred for symptomatic patients needing a rapid response, whereas IO/IO combinations may offer greater potential for treatment cessation. He brought up a key distinction in RCC, which is that re-instituting PD-1/PD-L1 inhibition upon progression in the metastatic setting has generally shown no benefit. Dr Levy brought a broad scope to the GU cancer discussion through his lung cancer expertise, introducing parallels between the treatment paradigms. The interview provided an opportunity to show the importance of creating connections across oncology specialties to bring nuanced perspectives to future advances in clinical research and patient care.

In the second episode of this three-part series, we delve into the science behind Refractory Chronic Cough (RCC), focusing on the role of neuronal hypersensitivity and how the cough reflex becomes dysregulated.1 Join leading experts as they explain the neurobiology of RCC, discuss the latest research, and share practical insights for identifying RCC in clinical practice.

Message from Terry Williams on November 9, 2025

Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management.  You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:      Dr. Monty Pal    @montypal   Dr. Pauline Funchain @FunchainMD Follow ASCO on social media:       @ASCO on Twitter      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn     Disclosures: Dr. Monty Pal:     Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview    Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck

Message from Terry Williams on November 2, 2025

Wrapping up our live ESMO 2025 coverage from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review pivotal kidney cancer data, including RAMPART's results, emerging first-line combinations from KEYMAKER-U03 and more, offering a forward-looking view of where RCC research is heading next.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Message from Aaron Lewis on October 26, 2025

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Matthew D. Taylor draws on more than two decades of leadership in both public service and real estate. A former 20‑year director of a large Health and Human Services Agency in Ventura County—where he also served as a federal grant writer, project manager and power contract negotiator—Matthew transitioned into residential real estate over 21 years ago. Since then he has excelled in resale and new home sales, earning recognition as Agent of the Month, Top Ten Agent of the Year and #1 in closed transactions, and he has taught aspiring agents as a certified instructor at the Arizona School of Real Estate and Business. A former associate broker with Mandalay Homes, Matthew specializes in luxury, golf and resort‑style properties, custom homes and equestrian estates. Licensed in multiple states and now focused on California, he is also a coach, trainer and mentor, holding designations including ABR, SRS, MRP, GRI, CDPE, NHS and RCC.In this episode we explore what it means to be a true leader in real estate and how a spirit of service can transform your business. Matthew shares insights from his diverse career—from managing public agencies to coaching agents—highlighting the importance of servant leadership, ethical practice and mentorship. We discuss how putting others first builds trust, fosters long‑term relationships and enhances professional growth, and Matthew offers practical advice for agents looking to lead by example and elevate those around them.You Can Find Matthew @:Instagram: https://www.instagram.com/taylorrealestateconsultants/Website: https://www.taylorrealestateconsultants.com/Youtube: https://www.youtube.com/@livingventuracounty/videos

Message from Terry Williams on October 19, 2025

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Andy talks about the Cardi B and Bia feud, covering Destroyer in Boston, not having any heat or hot water in his home, and Kodaline breaking up. We listen to clips of Yungblud talking about which American rock bands are cowboys and which ones are pirates, and a man calling out Freddy Kreuger while standing on the corner of Elm Street. On Rachel's Chart Chat, Rachel from Des Moines looks at Rush's top ten best-performing songs on the Top Tracks/Mainstream Rock airplay chart. You can find a playlist Rachel put together for this RCC segment here. Follow Rachel on Last.fm here.

Message from Terry Williams on October 12, 2025

Matt Slick Live (Live Broadcast of 10/09/2025) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: A Caller Inquires About CARM's Three Online Study Courses/Matt Briefly Discusses One of his Novels/ Matt Discusses some Doctrines Found in Reformed Theology/Election/Predestination??????/ Chat Questions Answered—Prophets and Apostles/What is an Argument against Sola Scriptura?/Matt Discusses some of the Teachings of the RCC and the EO/What is the Purpose of Water Baptism?/ October 9, 2025

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Message from Terry Williams on October 5, 2025

On May 7th, 2025, the Roman Catholic Church convened a Conclave which would result in the selection of the new Pope Leo. In this timely Corsi Nation encore presentation, Dr. Jerome Corsi revisits his powerful interview with analyst and former Biden stenographer Mike McCormick, who exposes the dark influence of Hollywood and the Deep State through the film Conclave — a movie centered on the coerced selection of a questionable Pope.McCormick and Dr. Corsi break down:

[Dave Hunt's newsletter on Anti-Semitism is as relevant today as it was when it was published 37 years ago. The Roman Catholic Church (RCC) finally recognized the State of Israel, establishing diplomatic relations on December 30, 1993, over 45 years after the modern nation was founded. The RCC also recognized the (non-existent) State of Palestine on June 26, 2015.The RCC continues to believe that the Roman Catholic Church is the new Israel. The Catechism of the Catholic Church, published in 1994, says, “…from the beginning of his ministry, the Lord Jesus instituted the Twelve as ‘the seeds of the new Israel and the beginning of the sacred hierarchy.'”1]

Matt Slick Live (Live Broadcast of 10/01/2025) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: A Caller Wants Advice on a Personal Supernatural Experience/Living a Sanctified Life/ A Caller asks About The Death of Voddie Baucham/ Does Protestantism Believe that "Mystery Babylon" is the RCC?/Views of Interpreting End Times/Making Judgments/ October 1, 2025

Matt Slick Live (Live Broadcast of 09/30/2025) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Recounts his Interaction with those who Evangelized him/Errors of the RCC and the Need to Study God's Word/ Does Scripture Limit the Number of Children we Should Have?/ Is The World Turning Against Israel?/ Adam and Eve and The Tree of Life?/ A Question About the Capabilities of the Upcoming Website/ There Are no Women Authors of Bible Books—What Does This Mean?/ A Question on The Existence of God and One of Matt's Arguments/A Discussion of Logical Approaches to God's Nature/ September 30, 2025

Download our free app to access this and all of our teachings. Follow this link: https://app.jotform.com/241517009397156 Note - **You will have to open in an external webpage to download it to your home page ** Subscribe to our podcast by searching for "RCC in the HD Podcast" on your favorite podcast app, Itunes, or by searching the web. You may also find us at MichaelBurchett.org. May the Lord bless you abundantly as you study His Word.

Message from Aaron Lewis on September 28, 2025

In this episode of The Voice of Retail Podcast, host Michael LeBlanc sits down with Michael Zabaneh, Vice President, Sustainability at the Retail Council of Canada, for an in-depth discussion on the future of sustainability in Canadian retail. With over 15 years of experience spanning global recycling ventures, luxury brands, and corporate advocacy, Michael shares a front-row perspective on how environmental priorities are reshaping the retail industry.Michael begins by unpacking the complexities of extended producer responsibility (EPR)—the regulatory framework shifting waste management costs from municipalities to producers and retailers. He explains how retailers are responsible not only for their private labels but also as first importers, making EPR compliance one of the most pressing and costly issues for Canadian retailers today. With more than 110 EPR programs across the country and compliance costs approaching $3 billion, this is a boardroom-level challenge with major implications for consumers and businesses alike.The conversation also dives into how retailers are embedding sustainability into their core strategies. From cutting energy costs with smart temperature controls and LED lighting to integrating renewable energy and recycling programs, sustainability initiatives increasingly deliver both environmental and financial benefits. Michael emphasizes that for mid-sized and independent retailers, sustainability is no longer optional—procurement, supply chain decisions, and operational efficiencies must all reflect responsible practices.Looking ahead, Michael previews the Retail Council of Canada's Retail Sustainability Conference 2025, now expanded to a two-day format on October 29–30 in Toronto. With workshops on zero-emission vehicles and harmonizing EPR regulations across provinces, the event is designed to deliver solutions-oriented dialogue. Attendees will also hear from Sheri Flies, SVP Global Sustainability & Compliance at Costco, and Jim Andrew, EVP & Chief Sustainability Officer at PepsiCo, alongside panels featuring McDonald's, Walmart, Loblaw, Unilever, and Procter & Gamble.Michael highlights how this event has quickly become one of RCC's flagship conferences, convening retailers, supply chain leaders, regulators, and governments to push forward practical solutions amidst economic uncertainty, climate commitments, and global plastic challenges.  The Voice of Retail podcast is presented by Hale, a performance marketing partner trusted by brands like ASICS, Saje, and Orangetheory to scale with focus and impact. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fifth year in a row, the National Retail Federation has designated Michael as on their Top Retail Voices for 2025, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Message from Terry Williams on September 21, 2025

Message from Terry Williams on September 14, 2025

Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies.PresenterPeter Dicpinigaitis, MDProfessor of MedicineAlbert Einstein College of MedicineDivision of Critical Care MedicineMontefiore Medical CenterDirector, Montefiore Cough CenterBronx, New YorkLink to full program:https://bit.ly/4kweynG

Message from Aaron Lewis on September 7, 2025

Matt Slick Live (Live Broadcast of 08/27/2025) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Announces The Release of New WebSite Articles—Priesthood Table of The RCC and EO, Levels of Reward in Heaven/The Need to Equip The Saints so We Can Reach The Lost/ Caller Wants to Know if Matt Has a "Go To" Bible Verse to Live By/Which Translation Does He Prefer, and Why there are Currently so Many/ Matt Discusses the Current State of Artificial Intelligence for Websites/Email Question—A "Oneness" Dress Issue/ Can God Destroy a "Spirit?"/Why Eternal "Punishment" Requires Experience/ Matt Discusses Problems with "Soul Sleep" and "Annihilationism"/How this Relates to The Dual Nature of Jesus/A "Oneness" Problem Examined/ 1 Peter 2:8—Does God Appoint Disobedience?/ August 27, 2025

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.